Prof Pierce Chow

Pierce Chow graduated MBBS and PhD from the National University of Singapore. He trained in General Surgery at the Singapore General Hospital and won the Chapter of Surgeons Gold Medal at the conjoint M.Med(Surgery)/FRCS(Edinburgh) examination. Following advanced surgical training in Singapore, he completed a clinical Fellowship in Hepato-Pancreato-Biliary Surgery and Liver Transplantation with Professor Russell Strong in Australia and was subsequently appointed Consultant Surgeon at the Singapore General Hospital.

Pierce is currently tenured professor at the Duke-NUS Medical School and director of the Comprehensive Liver Cancer Clinic at the National Cancer Center Singapore. He is an NMRC funded Senior Clinician Scientist and Principal Investigator (PI) of the NMRC National Flagship Program in Liver Cancer, the PLANet study. He is also funded by BMRC to conduct, in collaboration with industry, the prospective cohort study of patients at high risk of developing liver cancer (ELEGANCE). He has authored more than 300 peer-reviewed papers and has published in the Lancet, Cell, JCO, Nature Cancer, Journal of Hepatology, Gut and other top journals.

Besides clinical work and research, Pierce is also very active in medical education. He is the inaugural and current director of the PhD Program in Clinical and Translational Science at the Duke-NUS Medical School Singapore. He was the inaugural director of the pre-clinical Normal Body course in the same medical school and the founding president of the College of Clinician Scientists at the Academy of Medicine Singapore.

Pierce is Protocol Chair of the Asia-Pacific Hepatocellular Carcinoma (AHCC) Trials Group and President of the Asia-Pacific Primary Liver Cancer Expert Association (APPLE) (2026–2028). He has conducted 14 prospective multi-center clinical studies that has enrolled more than 6000 patients from 64 sites across 17 countries and territories in the Asia-Pacific. In recognition of his outstanding work in clinical and translational liver cancer research, Pierce was conferred the NMRC Outstanding Clinician Scientist Award in 2012 and the NMRC Singapore Translational Research (STaR) Investigator Award in 2025. In 2023, he was inducted into Duke-NUS Medical School’s Hall of Master Academic Clinicians.

• PhD, National University of Singapore, 2004
• Fellowship Diploma, Academy of Medicine, Singapore, 1999
• Fellowship Diploma (FRCS), Royal College of Surgeons, Edinburgh, 1994
• M.Med (Surgery), National University of Singapore, 1994
• MBBS, National University of Singapore, 1989

• President, The Asia-Pacific Primary Liver Cancer Expert Association (APPLE) 2026–2028
• Member, Nominations and Appointments (NAC) Committee, Duke-NUS 2025–2028
• Panel Member, CONVERT-HCC International Consensus Panel on Conversion Therapy 2026
• Member, Advisory Committee, SingHealth Experimental Medicine Centre (SEMC) 2025–2028
• Co-Chair, Research and Scholarship Committee, Duke-NUS Medical School
• Founding President, College of Clinician Scientists, Academy of Medicine Singapore
• Research Director, Institute of Molecular Cell Biology (IMCB)
• Associate Faculty, Senior Group Leader, Genome Institute of Singapore (GIS)
• Protocol Chair, Asia-Pacific Hepatocellular Carcinoma (AHCC) Trials Group
• Fellow, The Royal College of Surgeons of Edinburgh (RCSEd)
• Fellow, Singapore Medical Association  

• Singapore Translational Research (STaR) Investigator Award, 2025
• Outstanding Contribution – Inaugural President, College of Clinician Scientists, Academy of Medicine Singapore, 2025
• Master Academic Clinician Award, Duke-NUS Graduate Medical School, 2023 
• Long Serving Clinical Faculty, Duke-NUS Graduate Medical School, 2022
• Singapore Health Quality Service Awards, Silver Award, 2020
• Senior Investigator Clinician Scientist Award, National Medical Research Council, 2018
• Honorary Fellow, Academy of Medicine Malaysia, 2017
• Honorary Fellow, Hepatology Society of the Philippines, 2016
• National Day Awards, Pingkat Bakti Setia, Government of Singapore, 2016
• NMRC Translational and Clinical Research Flagship Program Award, 2016
• SingHealth Duke-NUS Research Team Award, 2nd Prize, 2015
• Outstanding Faculty for Engagement Award (Normal Body), Duke-NUS, 2013
• Outstanding Faculty for Engagement Award (Surgery), Duke-NUS, 2012
• Outstanding Faculty for Advocacy Award (Normal Body), Duke-NUS, 2012
• National Outstanding Clinician Scientist Award, National Medical Research Council, 2012
• Pioneer Award, Duke-NUS Graduate Medical School, 2011
• Singapore Health Quality Service Award, Silver, 2011
• Outstanding Educator Award, Duke-NUS Graduate Medical School, 2010
• Senior Investigator Clinician Scientist Award, National Medical Research Council, 2010
• Service With A Heart Award, Singapore General Hospital, 2010
• Outstanding Educator Award, Duke-NUS Graduate Medical School, 2009
• Excellent Publication Award, SingHealth (Singapore General Hospital), 2006
• Excellent Service Award (Gold), Healthcare. Spring Singapore, 2004
• SARS Courage Medal, Government of Singapore, 2003
• Sir James Fraser Fellow, Royal College of Surgeons of Edinburgh, 2002
• HMDP Clinical Fellowship in HPB Surgery and Liver Transplantation, 1999
• NMRC - Singapore Totalisator Board Medical Research Fellowship, 1997
• Seah Cheng Siang Prize GE Society of Singapore, Best original research, 1997
• NMRC - Kwek Hong Png Medical Research Fellowship, 1995
• Young Surgeon's Award Academy of Medicine, Singapore. Best original research, 1995
• Chapter of Surgeon's Gold Medal Conjoint M.Med (Surgery)/FRCS (Edin) Exam, 1994  

• Restoring Bile Acid Homeostasis Via Lifestyle Adjustments to Prevent the Development of Liver Cancer https://clinicaltrials.gov/ct2/show/NCT07111130 (AHCC14 REBALANCE)
• Precision Medicine in Liver Cancer across an Asia-Pacific Network 2.0 https://clinicaltrials.gov/study/NCT05516628 (AHCC12 EMPHASIS & AHCC13) 
• A multi-national, double-blind, placebo-control, randomized phase II trial to compare the safety and efficacy of SIR-Spheres (Y-90 resin microspheres) followed by atezolizumab plus bevacizumab ver-sus SIR-Spheres in patients with locally advanced HCC https://clinicaltrials.gov/study/NCT05377034 (AHCC09 STRATUM)
• Development of a companion diagnostic test kit for selective internal radiation therapy and immunotherapy for hepatocellular carcinoma (HCC): A prospective clinical translational study
• Prospective Cohort Study of Changes in Circulatory MicroRNA after Surgical Resection of Hepatocellular Carcinoma https://clinicaltrials.gov/ct2/show/NCT05148572 (AHCC11 PROSECT)
• Early detection of hepatocellular carcinoma (HCC): miRNA, microbiome and imaging biomarkers in the evolution of chronic liver disease in a high-risk prospective cohort https://clinicaltrials.gov/ct2/show/NCT04965259 (AHCC10 ELEGANCE)
• Decoding global gene expression in liver cancer through deep learning and standard-of-care clinical imaging
• A Patient-Specific Diagnostic and Predictive Platform for Precision Medicine in HCC
• Hepatocellular Carcinoma (HCC) Registry in Asia http://clinicaltrials.gov/ct2/show/NCT03233360 (AHCC08)
• A Prospective Study to develop a Genomics-Immunomics- Phenomics Platform for Precision Medicine in HCC
• Comprehensive interrogation of the epigenetics promoter and enhancer landscape in HCC to identify aberrant regulatory mechanisms associated with HCC
• The use of LiverMultiScan ("LMS") to analyse HCC patients' MRI scans for improved monitoring of patients' prognosis and selection of therapy
• Post-SIR Spheres® surgery study (P4S): a retrospective analysis in patients with primary liver tumours or secondary hepatic metastases
• Artificial Liver Platform for Next-Generation Drug Discovery and Development
• Precision Medicine in Liver Cancer across an Asia-Pacific Network http://clinicaltrials.gov/ct2/show/NCT03267641 (AHCC07 PLANET)
• Phase III Multi-Centre Open-Label Randomized Controlled Trial of Selective Internal Radiation Therapy (SIRT) Versus Sorafenib in Locally Advanced Hepatocellular Carcinoma http://clinicaltrials.gov/ct2/show/NCT01135056 (AHCC06 SIRveNIB)
• Effect of YQ23 on Radiation sensitization in a Hepatoma Model
• Study of SIR-Spheres plus Sorafenib as 1st Line Treatment for Non-Resectable Primary Hepatocellular Carcinoma http://clinicaltrials.gov/ct2/show/NCT00712790 (AHCC05)
• A Study of the Safety Profile of Three Escalating Radioactivity Levels of 32P BioSilicon Delivered with the SIMPL Needle as Intratumoural Implantations in Patients With Unresectable Hepatocellular Carcinoma https://clinicaltrials.gov/ct2/show/NCT00247260 (AHCC04)   
• Randomized Phase III Trial to determine the Effectiveness of Megestrol Acetate in treating Patients who have Liver Cancer that cannot be removed by surgery http://www.clinicaltrials.gov/ct/gui/show/NCT00041275 (AHCC02)
• Phase III Randomized Study of High Dose Tamoxifen versus Placebo in Patients with Inoperable Hepatocellular Carcinoma http://clinicaltrials.gov/ct/show/NCT00003424 (AHCC01)

Selected Publications

• Zhang Y, Sekar K, Phua CZJ, …, Chow PKH. (2026) Clonal diversity underpins distinct modes of recurrence in hepatocellular carcinoma: the PLANet cohort study. Gut. Published Online First: 21 July 2026. doi: 10.1136/gutjnl-2026-338227
• Yopp A, Chen M, Cheng AL, …, Chow PKH. (2026) Updated data from IMbrave050: Adjuvant atezolizumab plus bevacizumab for high-risk hepatocellular carcinoma. J Hepatol. doi: 10.1016/j.jhep.2026.01.006
• Malik AK, Geh D, Jeffry Evans TR, Chow PKH, Mann DA, White SA. (2026) Improving surgical treatments for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. doi: 10.1038/s41575-025-01143-y
• Seshachalam VP, Sari IN, Toh K, …, Chow PKH. (2026) Multiomics and multi-region spatial transcriptome analysis reveal cellular networks and pathways associated with HCC recurrence. JHEP Rep. doi: 10.1016/j.jhepr.2026.101790
• Lee JYJ, Zhang J, Chew SC, …, Chow PKH. (2026) Spatially-guided metabolomics profiling of metabolic regions in human tumor tissues. Mol Syst Biol. doi: 10.1038/s44320-026-00205-w
• Chan SL, Sun H, Xu Y, …, Chow PKH, Yau T, Kudo M, Fan J, Zhou J. (2025) The Lancet Commission on addressing the global hepatocellular carcinoma burden: comprehensive strategies from prevention to treatment. Lancet. doi: 10.1016/S0140-6736(25)01042-6
• Li Z, Pai R, Gupta S, …, Chow PKH et al. (2024) Presence of onco-fetal neighborhoods in hepatocellular carcinoma is associated with relapse and response to immunotherapy. Nat Cancer. doi: 10.1038/s43018-023-00672-2
• Chen JB, Kaya NA, Zhang Y, …, Chow PKH et al. (2024) A multimodal atlas of hepatocellular carcinoma reveals convergent evolutionary paths and 'bad apple' effect on clinical trajectory. J Hep. doi: 10.1016/j.jhep.2024.05.017
• Qin S, Chen M, Cheng A-L, Kaseb AO, Kudo M, Lee HC, Yopp AC, Zhou J, Wang L, Wen X, Heo J, Tak WY, Nakamura S, Numata K, Uguen T, Hsiehchen D, Cha E, Hack SP, Lian Q, Ma N, Spahn JH, Wang Y, Wu C, Chow PKH (2023). Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial. The Lancet. https://doi.org/10.1016/S0140-6736(23)01796-8 
• Chan JJ, Zhang B, Chew XH, Salhi A, Kwok ZH, Lim CY, …, Chen L, Gao X, Chow PKH, Yang H, Tay Y. (2022) Pan-cancer pervasive upregulation of 3' UTR splicing drives tumourigenesis. Nat. Cell Bi-ol., https://doi.org/10.1038/s41556-022-00913-z 
• Sharma A, Seow JJW, Dutertre CA, Pai R, Blériot C, Mishra A, Wong RMM, Singh GSN, Sudhagar S, Khalilnezhad S, Erdal S, Teo HM, Khalilnezhad A, Chakarov S, Lim TKH, Fui ACY, Chieh AKW, Chung CP, Bonney GK, Goh BK, Chan JKY,  Chow PKH, Ginhoux F, DasGupta R. (2020) Onco-fetal Reprogramming of Endothelial Cells Drives Immunosuppressive Macrophages in Hepatocellular Carcinoma. Cell, 183(2):377-394.e21. https://doi.org/10.1016/j.cell.2020.08.040. PMID: 32976798
• Nguyen PHD, Ma S, Phua CZJ, Kaya NA, Lai HLH, Lim CJ, Lim JQ, Wasser M, Lai L, Tam WL, Lim TKH, Wan WK, Loh T, Leow WQ, Pang YH, Chan CY, Lee SY, Cheow PC, Toh HC, Ginhoux F, Iyer S, Kow AWC, Young Dan Y, Chung A, Goh BKP, Albani S,  Chow PKH, Zhai W, Chew V. (2021) Intratumoural immune heterogeneity as a hallmark of tumour evolution and progression in hepatocellular carcinoma. Nat Commun., 12(1):227. https://doi.org/10.1038/s41467-020-20171-7. PMID: 33431814.
• Zhai WW, Lai H, Kaya NA, Chen J, Yang HC, Lu BX, …, Tam WL, Toh HC, Foo RSY,  Chow PKH. (2021) Dynamic phenotypic heterogeneity and the evolution of multiple RNA subtypes in Hepatocellular Carcinoma: the PLANET study, Nat. Sci. Rev. https://doi.org/10.1093/nsr/nwab192
• Chow PKH, Mihir Gandhi, Say-Beng Tan, et al. (2018) SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma. J. Clin. Oncol., JCO2017760892. https://doi.org/10.1200/JCO.2017.76.0892.
• Chew, V., Lee, Y.H., Pan, L., Nasir, N.J.M., Lim, C.J., Chua, C., Lai, L., Hazirah, S.N., Lim, T.K.H., Goh, B.K.P., Chung, A., Lo, R.H.G., Ng, D., Filarca, R.L.F, Albani, S., and Chow, P.K.H. (2018). Immune Activation Underlies a Sustained Clinical Response to Yttrium-90 Radioembolisation in Hepatocellular Carcinoma. Gut. pii: gutjnl-2017-315485. https://doi.org/10.1136/gutjnl-2017-315485.